Tectonic Therapeutic, Inc. Common Stock (TECX) is a publicly traded Healthcare sector company. As of May 21, 2026, TECX trades at $25.25 with a market cap of $522.68M and a P/E ratio of -6.89. TECX moved +5.61% today. Year to date, TECX is +46.32%; over the trailing twelve months it is +17.43%. Its 52-week range spans $13.70 to $61.07. Analyst consensus is strong buy with an average price target of $80.71. Rallies surfaces TECX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Tectonic Therapeutic Secures $236.9M Runway and Advances TX45, TX2100 Trials: Tectonic Therapeutic held $236.9 million in cash as of March 31, 2026, securing operational runway into Q4 2028 and supporting ongoing trials. The company advanced its TX45 APEX Phase 2 enrollment nearing completion, initiated TX45 ALPINE Phase 2 in PH-ILD, and dosed four cohorts in TX2100 Phase 1a.
| Metric | Value |
|---|---|
| Price | $25.25 |
| Market Cap | $522.68M |
| P/E Ratio | -6.89 |
| EPS | $-4.05 |
| Dividend Yield | 0.00% |
| 52-Week High | $61.07 |
| 52-Week Low | $13.70 |
| Volume | 1 |
| Avg Volume | 0 |
| Revenue (TTM) | $-80.32M |
| Net Income | $-74.15M |
| Gross Margin | 0.00% |
8 analysts cover TECX: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $80.71.